Conference Coverage

Demand rises for national melanoma screening program


 

EXPERT ANALYSIS FROM SDEF HAWAII DERMATOLOGY SEMINAR

First do no harm

Dr. Halpern offered a note of caution regarding melanoma screening: Although it sounds great in theory because it’s relatively cheap, the lesions are accessible on the surface of the skin, and there is the potential to save many life-years, it’s also imperative to consider the potential harms. Perhaps the biggest of these, Dr. Halpern said, is the psychological damage caused by turning a patient with an indolent, low-risk melanoma or nonmelanoma skin cancer into a cancer patient.

"We have to be really, really careful to look at the harms involved in screening. To my mind, one of the biggest problems of melanoma screening is the psychological harm we do by giving people cancer. I’m especially bothered about the way we do that with patients who develop melanoma in situ or microinvasive disease," he said.

"Believe me, if I had melanoma in situ or microinvasive melanoma, I would want you to find it and take if off for me. What I don’t want you to do is to turn me into a cancer patient. I don’t think that’s in the patient’s best interest whatsoever. We don’t do it intentionally, but as dermatologists we have this tendency to dramatically overplay the importance of these diagnoses," Dr. Halpern said.

Dr. Halpern reported having financial relationships with Scibase, DermTech, Caliber, and Canfield.

SDEF and this news organization are owned by the same parent company.

bjancin@frontlinemedcom.com

Pages

Recommended Reading

Melanomas were less invasive at diagnosis in patients with established dermatologist
MDedge Dermatology
Immunotherapy for melanoma progresses with some interesting response patterns
MDedge Dermatology
New study supports imiquimod for lentigo maligna
MDedge Dermatology
What’s old is new again for actinic keratoses treatment
MDedge Dermatology
Substantial delay seen in melanoma surgery for Medicare patients
MDedge Dermatology
Increased Risk for Melanoma in Men With Prostate Cancer: Implications for Clinical Practice?
MDedge Dermatology
House panel chides FDA for inaction on sunscreens
MDedge Dermatology
First-Degree Relatives of Melanoma Patients May Experience Counterphobia
MDedge Dermatology
Monoclonal antibody pinpoints BRAF status in melanoma
MDedge Dermatology
New guidelines address primary cutaneous T-cell lymphoproliferative disorders
MDedge Dermatology